Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 37 | 2020 | 2163 | 4.520 |
Why?
|
| Transcranial Direct Current Stimulation | 7 | 2018 | 111 | 3.520 |
Why?
|
| Stroke Rehabilitation | 8 | 2019 | 335 | 2.810 |
Why?
|
| Recovery of Function | 11 | 2018 | 506 | 2.240 |
Why?
|
| Brain Ischemia | 13 | 2018 | 665 | 1.850 |
Why?
|
| Upper Extremity | 4 | 2017 | 112 | 1.220 |
Why?
|
| Brain | 8 | 2017 | 2176 | 1.070 |
Why?
|
| Motor Cortex | 2 | 2018 | 158 | 1.070 |
Why?
|
| Pyramidal Tracts | 4 | 2017 | 45 | 0.980 |
Why?
|
| Fibrinolytic Agents | 3 | 2017 | 377 | 0.840 |
Why?
|
| Tyrosine | 3 | 2017 | 196 | 0.810 |
Why?
|
| Functional Laterality | 4 | 2017 | 240 | 0.800 |
Why?
|
| Carotid Stenosis | 3 | 2017 | 163 | 0.790 |
Why?
|
| Ischemic Preconditioning | 3 | 2018 | 31 | 0.790 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2016 | 296 | 0.750 |
Why?
|
| Ischemic Attack, Transient | 2 | 2018 | 167 | 0.680 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 16 | 0.670 |
Why?
|
| Humans | 50 | 2020 | 68618 | 0.650 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 71 | 0.640 |
Why?
|
| Cerebrovascular Disorders | 2 | 2017 | 182 | 0.630 |
Why?
|
| Berberine | 1 | 2018 | 3 | 0.620 |
Why?
|
| Evoked Potentials, Motor | 1 | 2018 | 63 | 0.610 |
Why?
|
| Curcumin | 1 | 2018 | 23 | 0.610 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2017 | 239 | 0.610 |
Why?
|
| Brain Waves | 1 | 2018 | 30 | 0.610 |
Why?
|
| Electromagnetic Fields | 1 | 2018 | 66 | 0.600 |
Why?
|
| Thalamus | 1 | 2018 | 82 | 0.600 |
Why?
|
| Lovastatin | 1 | 2018 | 78 | 0.590 |
Why?
|
| Treatment Outcome | 18 | 2020 | 7029 | 0.590 |
Why?
|
| Aged | 23 | 2020 | 14862 | 0.590 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 87 | 0.560 |
Why?
|
| Biological Products | 1 | 2018 | 78 | 0.560 |
Why?
|
| Movement Disorders | 1 | 2017 | 58 | 0.560 |
Why?
|
| Ultrasonography | 2 | 2017 | 453 | 0.550 |
Why?
|
| Male | 32 | 2020 | 37321 | 0.540 |
Why?
|
| Female | 32 | 2020 | 38074 | 0.540 |
Why?
|
| Middle Aged | 26 | 2020 | 21147 | 0.530 |
Why?
|
| Thrombectomy | 4 | 2020 | 238 | 0.530 |
Why?
|
| Hepatic Artery | 1 | 2015 | 25 | 0.530 |
Why?
|
| Vasoconstriction | 1 | 2015 | 81 | 0.510 |
Why?
|
| Atherosclerosis | 1 | 2017 | 204 | 0.510 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2015 | 17 | 0.500 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2015 | 22 | 0.500 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 1851 | 0.490 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 79 | 0.490 |
Why?
|
| Time Factors | 10 | 2017 | 4655 | 0.480 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 274 | 0.480 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2014 | 4 | 0.470 |
Why?
|
| Antihypertensive Agents | 3 | 2015 | 498 | 0.460 |
Why?
|
| Hospitalization | 5 | 2014 | 978 | 0.460 |
Why?
|
| Optic Nerve Diseases | 1 | 2014 | 31 | 0.460 |
Why?
|
| Demyelinating Diseases | 1 | 2014 | 57 | 0.460 |
Why?
|
| Biomedical Research | 1 | 2017 | 310 | 0.450 |
Why?
|
| Hypertension | 4 | 2016 | 1535 | 0.440 |
Why?
|
| Thrombolytic Therapy | 2 | 2016 | 233 | 0.430 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2010 | 21 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 2223 | 0.410 |
Why?
|
| Blood Pressure | 2 | 2015 | 1451 | 0.390 |
Why?
|
| Cognition | 1 | 2015 | 513 | 0.380 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 694 | 0.350 |
Why?
|
| Neurosyphilis | 1 | 2009 | 7 | 0.340 |
Why?
|
| Disability Evaluation | 3 | 2017 | 298 | 0.330 |
Why?
|
| Aged, 80 and over | 10 | 2018 | 4848 | 0.330 |
Why?
|
| Animals | 8 | 2018 | 20881 | 0.310 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2013 | 413 | 0.310 |
Why?
|
| Quality of Life | 2 | 2015 | 1515 | 0.290 |
Why?
|
| Anisotropy | 2 | 2017 | 105 | 0.280 |
Why?
|
| Adult | 10 | 2018 | 21403 | 0.260 |
Why?
|
| Myocardial Infarction | 2 | 2016 | 807 | 0.260 |
Why?
|
| Aspirin | 2 | 2018 | 295 | 0.260 |
Why?
|
| Patient Discharge | 4 | 2019 | 294 | 0.260 |
Why?
|
| Recurrence | 4 | 2018 | 948 | 0.260 |
Why?
|
| Prospective Studies | 5 | 2019 | 3705 | 0.250 |
Why?
|
| Retrospective Studies | 8 | 2020 | 7277 | 0.250 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 373 | 0.240 |
Why?
|
| Peroneal Nerve | 2 | 2015 | 6 | 0.240 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 1465 | 0.230 |
Why?
|
| Double-Blind Method | 3 | 2019 | 1738 | 0.220 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2015 | 86 | 0.220 |
Why?
|
| Electric Stimulation Therapy | 2 | 2015 | 147 | 0.210 |
Why?
|
| Length of Stay | 2 | 2019 | 780 | 0.200 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 3259 | 0.200 |
Why?
|
| Adolescent | 5 | 2018 | 8912 | 0.190 |
Why?
|
| Developed Countries | 2 | 2017 | 8 | 0.180 |
Why?
|
| Risk Factors | 6 | 2017 | 5731 | 0.180 |
Why?
|
| Wrist | 1 | 2019 | 24 | 0.170 |
Why?
|
| Vibration | 1 | 2019 | 32 | 0.170 |
Why?
|
| Physical Stimulation | 1 | 2019 | 67 | 0.170 |
Why?
|
| Developing Countries | 2 | 2017 | 106 | 0.170 |
Why?
|
| Safety | 1 | 2019 | 145 | 0.160 |
Why?
|
| Cerebral Angiography | 2 | 2017 | 151 | 0.160 |
Why?
|
| Intra-Abdominal Fat | 1 | 2018 | 11 | 0.160 |
Why?
|
| Alkaline Phosphatase | 1 | 2018 | 71 | 0.150 |
Why?
|
| Information Systems | 1 | 2018 | 45 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 87 | 0.150 |
Why?
|
| Medical Futility | 1 | 2018 | 31 | 0.150 |
Why?
|
| Sample Size | 1 | 2018 | 79 | 0.150 |
Why?
|
| Blood Glucose | 2 | 2018 | 631 | 0.150 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 137 | 0.150 |
Why?
|
| Organ Size | 1 | 2018 | 242 | 0.150 |
Why?
|
| Disease Progression | 2 | 2017 | 1038 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1054 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 186 | 0.140 |
Why?
|
| Cerebral Revascularization | 2 | 2014 | 45 | 0.140 |
Why?
|
| Corpus Callosum | 1 | 2016 | 29 | 0.140 |
Why?
|
| Hypolipidemic Agents | 1 | 2017 | 82 | 0.140 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 54 | 0.140 |
Why?
|
| Carotid Artery Diseases | 1 | 2017 | 83 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 291 | 0.140 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 133 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 123 | 0.140 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 161 | 0.140 |
Why?
|
| Ticlopidine | 1 | 2016 | 118 | 0.140 |
Why?
|
| Lipids | 1 | 2018 | 298 | 0.140 |
Why?
|
| Polygonaceae | 1 | 2016 | 1 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2324 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 649 | 0.130 |
Why?
|
| Brain Diseases | 1 | 2016 | 78 | 0.130 |
Why?
|
| Axons | 1 | 2017 | 139 | 0.130 |
Why?
|
| Glucosides | 1 | 2016 | 16 | 0.130 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2016 | 15 | 0.130 |
Why?
|
| Ions | 1 | 2016 | 50 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 1 | 2017 | 296 | 0.130 |
Why?
|
| Body Weight | 1 | 2018 | 554 | 0.130 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 455 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2018 | 652 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 737 | 0.130 |
Why?
|
| Pneumonia | 1 | 2016 | 110 | 0.130 |
Why?
|
| Income | 1 | 2016 | 167 | 0.130 |
Why?
|
| Stilbenes | 1 | 2016 | 57 | 0.130 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 82 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 567 | 0.130 |
Why?
|
| Analysis of Variance | 1 | 2017 | 1040 | 0.130 |
Why?
|
| South Carolina | 3 | 2014 | 2752 | 0.130 |
Why?
|
| Metals | 1 | 2016 | 100 | 0.120 |
Why?
|
| Insulin | 1 | 2018 | 619 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 174 | 0.120 |
Why?
|
| Hemodynamics | 1 | 2017 | 705 | 0.120 |
Why?
|
| Stents | 2 | 2017 | 657 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 176 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2018 | 374 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2016 | 241 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 216 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 592 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 51 | 0.120 |
Why?
|
| Osmosis | 1 | 2014 | 38 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2018 | 718 | 0.110 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2014 | 37 | 0.110 |
Why?
|
| Malnutrition | 1 | 2014 | 28 | 0.110 |
Why?
|
| Racism | 1 | 2014 | 59 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 848 | 0.110 |
Why?
|
| Biomarkers | 2 | 2017 | 1593 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 445 | 0.110 |
Why?
|
| Research Design | 1 | 2018 | 729 | 0.110 |
Why?
|
| Risk | 2 | 2016 | 563 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2014 | 168 | 0.110 |
Why?
|
| Young Adult | 2 | 2018 | 5717 | 0.110 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 157 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 2083 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 362 | 0.110 |
Why?
|
| Infant | 2 | 2010 | 2891 | 0.110 |
Why?
|
| Neural Pathways | 1 | 2015 | 324 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2010 | 3187 | 0.110 |
Why?
|
| Liver | 1 | 2018 | 1118 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 268 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1293 | 0.100 |
Why?
|
| Hospital Mortality | 2 | 2014 | 384 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 581 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 3 | 2017 | 198 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 772 | 0.100 |
Why?
|
| Inflammation | 1 | 2018 | 1030 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2014 | 335 | 0.100 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 439 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2014 | 286 | 0.090 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2010 | 20 | 0.090 |
Why?
|
| Prognosis | 1 | 2015 | 2093 | 0.090 |
Why?
|
| Glasgow Coma Scale | 1 | 2010 | 65 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 940 | 0.090 |
Why?
|
| Mechanical Thrombolysis | 1 | 2010 | 29 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 378 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2550 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 334 | 0.090 |
Why?
|
| Rats | 1 | 2017 | 5300 | 0.080 |
Why?
|
| Telemedicine | 1 | 2017 | 700 | 0.080 |
Why?
|
| Age Factors | 2 | 2014 | 1864 | 0.080 |
Why?
|
| Child | 2 | 2010 | 6405 | 0.080 |
Why?
|
| Smoking | 1 | 2016 | 1452 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 329 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 880 | 0.080 |
Why?
|
| Pregnancy | 1 | 2014 | 2334 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2009 | 344 | 0.070 |
Why?
|
| Comorbidity | 1 | 2010 | 1426 | 0.060 |
Why?
|
| International Classification of Diseases | 2 | 2016 | 85 | 0.060 |
Why?
|
| Foot Orthoses | 2 | 2015 | 7 | 0.060 |
Why?
|
| Registries | 2 | 2018 | 733 | 0.060 |
Why?
|
| Ankle | 2 | 2015 | 45 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2010 | 2007 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2009 | 2455 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 931 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 1603 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2015 | 1330 | 0.040 |
Why?
|
| United States | 1 | 2010 | 7367 | 0.040 |
Why?
|
| China | 1 | 2018 | 138 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2017 | 38 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 89 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2017 | 82 | 0.040 |
Why?
|
| Databases, Bibliographic | 1 | 2017 | 14 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 117 | 0.030 |
Why?
|
| Cerebral Peduncle | 1 | 2016 | 1 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 62 | 0.030 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 366 | 0.030 |
Why?
|
| Internationality | 1 | 2016 | 74 | 0.030 |
Why?
|
| Plant Roots | 1 | 2016 | 22 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 125 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 951 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 211 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 52 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 61 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 413 | 0.030 |
Why?
|
| Telomere | 1 | 2014 | 59 | 0.030 |
Why?
|
| Foot | 1 | 2014 | 66 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.030 |
Why?
|
| Health Personnel | 1 | 2016 | 286 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 346 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 424 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1140 | 0.030 |
Why?
|
| Contrast Media | 1 | 2016 | 595 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2014 | 112 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 689 | 0.030 |
Why?
|
| Walking | 1 | 2015 | 241 | 0.030 |
Why?
|
| Brain Stem Infarctions | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2358 | 0.020 |
Why?
|
| Pons | 1 | 2010 | 35 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 237 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 39 | 0.020 |
Why?
|
| Basilar Artery | 1 | 2010 | 38 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 181 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 572 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2673 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1342 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2017 | 1034 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 2791 | 0.020 |
Why?
|
| Mice | 1 | 2014 | 8474 | 0.010 |
Why?
|